Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma

J Pijpe; G W van Imhoff; A Vissink; J E van der Wal; P M Kluin; F K L Spijkervet; C G M Kallenberg; H Bootsma

doi:10.1136/ard.2004.030684

Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma

J Pijpe, G W van Imhoff, A Vissink, J E van der Wal, P M Kluin, F K L Spijkervet, C G M Kallenberg, H Bootsma

Research output: Contribution to journal › Article › Academic › peer-review

94 Citations (Scopus)

Abstract

OBJECTIVES: To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjogren's syndrome (SS) and associated MALT lymphoma.

CASE REPORT: The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate. Four infusions of rituximab (375 mg/m(2)) weekly resulted in complete remission of the lymphoma. An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue. Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow.

DISCUSSION: Rituximab is a promising agent in the treatment of SS associated MALT lymphoma. In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS. This case report is the first to describe the effect of rituximab on histological and sialometric/chemical characteristics of SS. The efficacy of rituximab in the treatment of SS warrants further investigation.

Original language	English
Pages (from-to)	958-60
Number of pages	3
Journal	Annals of the Rheumatic Diseases
Volume	64
Issue number	6
DOIs	https://doi.org/10.1136/ard.2004.030684
Publication status	Published - Jun 2005
Externally published	Yes

Access to Document

10.1136/ard.2004.030684

Cite this

Pijpe, J., van Imhoff, G. W., Vissink, A., van der Wal, J. E., Kluin, P. M., Spijkervet, F. K. L., Kallenberg, C. G. M., & Bootsma, H. (2005). Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Annals of the Rheumatic Diseases, 64(6), 958-60. https://doi.org/10.1136/ard.2004.030684

@article{f51653592acb4eeeb39139c7707b4f56,

title = "Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma",

abstract = "OBJECTIVES: To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjogren's syndrome (SS) and associated MALT lymphoma.CASE REPORT: The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate. Four infusions of rituximab (375 mg/m(2)) weekly resulted in complete remission of the lymphoma. An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue. Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow.DISCUSSION: Rituximab is a promising agent in the treatment of SS associated MALT lymphoma. In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS. This case report is the first to describe the effect of rituximab on histological and sialometric/chemical characteristics of SS. The efficacy of rituximab in the treatment of SS warrants further investigation.",

author = "J Pijpe and {van Imhoff}, {G W} and A Vissink and {van der Wal}, {J E} and Kluin, {P M} and Spijkervet, {F K L} and Kallenberg, {C G M} and H Bootsma",

year = "2005",

month = jun,

doi = "10.1136/ard.2004.030684",

language = "English",

volume = "64",

pages = "958--60",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier",

number = "6",

}

Pijpe, J, van Imhoff, GW, Vissink, A, van der Wal, JE, Kluin, PM, Spijkervet, FKL, Kallenberg, CGM & Bootsma, H 2005, 'Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma', Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 958-60. https://doi.org/10.1136/ard.2004.030684

TY - JOUR

T1 - Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma

AU - Pijpe, J

AU - van Imhoff, G W

AU - Vissink, A

AU - van der Wal, J E

AU - Kluin, P M

AU - Spijkervet, F K L

AU - Kallenberg, C G M

AU - Bootsma, H

PY - 2005/6

Y1 - 2005/6

N2 - OBJECTIVES: To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjogren's syndrome (SS) and associated MALT lymphoma.CASE REPORT: The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate. Four infusions of rituximab (375 mg/m(2)) weekly resulted in complete remission of the lymphoma. An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue. Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow.DISCUSSION: Rituximab is a promising agent in the treatment of SS associated MALT lymphoma. In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS. This case report is the first to describe the effect of rituximab on histological and sialometric/chemical characteristics of SS. The efficacy of rituximab in the treatment of SS warrants further investigation.

AB - OBJECTIVES: To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjogren's syndrome (SS) and associated MALT lymphoma.CASE REPORT: The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate. Four infusions of rituximab (375 mg/m(2)) weekly resulted in complete remission of the lymphoma. An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue. Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow.DISCUSSION: Rituximab is a promising agent in the treatment of SS associated MALT lymphoma. In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS. This case report is the first to describe the effect of rituximab on histological and sialometric/chemical characteristics of SS. The efficacy of rituximab in the treatment of SS warrants further investigation.

U2 - 10.1136/ard.2004.030684

DO - 10.1136/ard.2004.030684

M3 - Article

C2 - 15576414

SN - 0003-4967

VL - 64

SP - 958

EP - 960

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 6

ER -

Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma

Abstract

Access to Document

Fingerprint

Cite this